Home › Marginal Zone Lymphoma › Tennessee
Marginal Zone Lymphoma clinical trials in Tennessee
8 studies for Marginal Zone Lymphoma are looking for participants at sites in Tennessee.
Cities in Tennessee
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
- Vanderbilt University/Ingram Cancer Center, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07763210A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
- Vanderbilt University, Nashvile
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05296070Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07121946A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.